Evidence map›Paper›PMID 34616097›Full record

ArticleNature chemical biology2021

Author Correction: Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth.

Bianca J Lee, Jacob A Boyer, G Leslie Burnett, Arun P Thottumkara, Nidhi Tibrewal, Stacy L Wilson, Tientien Hsieh, Abby Marquez, Edward G Lorenzana, James W Evans and 16 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Nature chemical biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors.

Bianca J Lee *Department of Biology, Revolution Medicines, Inc., Redwood City, CA, USA.
Jacob A Boyer *Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
G Leslie BurnettDepartment of Chemistry, Revolution Medicines, Inc., Redwood City, CA, USA.ORCID http://orcid.org/0000-0003-2514-9373
Arun P ThottumkaraDepartment of Chemistry, Revolution Medicines, Inc., Redwood City, CA, USA.
Nidhi TibrewalDepartment of Discovery Technologies, Revolution Medicines, Inc., Redwood City, CA, USA.
Stacy L WilsonDepartment of Biology, Revolution Medicines, Inc., Redwood City, CA, USA.
Tientien HsiehDepartment of Discovery Technologies, Revolution Medicines, Inc., Redwood City, CA, USA.
Abby MarquezDepartment of Discovery Technologies, Revolution Medicines, Inc., Redwood City, CA, USA.
Edward G LorenzanaDepartment of Biology, Revolution Medicines, Inc., Redwood City, CA, USA.
James W EvansDepartment of Biology, Revolution Medicines, Inc., Redwood City, CA, USA.
Laura HuleaGerald Bronfman Department of Oncology and Departments of Biochemistry and Experimental Medicine, Lady Davis Institute, McGill University, Montréal, QC, Canada.ORCID http://orcid.org/0000-0001-7585-7760
Gert KissDepartment of Discovery Technologies, Revolution Medicines, Inc., Redwood City, CA, USA.
Hui LiuScience for Life Laboratory, Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden.
Dong LeeDepartment of Non-clinical Development and Clinical Pharmacology, Revolution Medicines, Inc., Redwood City, CA, USA.
Ola LarssonScience for Life Laboratory, Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden.ORCID http://orcid.org/0000-0003-1412-1308
Shannon McLaughlanGerald Bronfman Department of Oncology and Departments of Biochemistry and Experimental Medicine, Lady Davis Institute, McGill University, Montréal, QC, Canada.
Ivan TopisirovicGerald Bronfman Department of Oncology and Departments of Biochemistry and Experimental Medicine, Lady Davis Institute, McGill University, Montréal, QC, Canada.
Zhengping WangDepartment of Non-clinical Development and Clinical Pharmacology, Revolution Medicines, Inc., Redwood City, CA, USA.
Zhican WangDepartment of Non-clinical Development and Clinical Pharmacology, Revolution Medicines, Inc., Redwood City, CA, USA.
Yongyuan ZhaoDepartment of Non-clinical Development and Clinical Pharmacology, Revolution Medicines, Inc., Redwood City, CA, USA.
David WildesDepartment of Biology, Revolution Medicines, Inc., Redwood City, CA, USA.
James B AggenDepartment of Chemistry, Revolution Medicines, Inc., Redwood City, CA, USA.
Mallika SinghDepartment of Biology, Revolution Medicines, Inc., Redwood City, CA, USA.
Adrian L GillDepartment of Chemistry, Revolution Medicines, Inc., Redwood City, CA, USA.
Jacqueline A M SmithDepartment of Biology, Revolution Medicines, Inc., Redwood City, CA, USA. jan@revmed.com.ORCID http://orcid.org/0000-0001-5028-8725
Neal RosenProgram in Molecular Pharmacology, Department of Medicine, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, NY, USA. rosenn@mskcc.org.ORCID http://orcid.org/0000-0002-8307-654X

Funding

Breast Cancer Research Foundation (BCRF) BCRF-20-141
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34616097

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.